Biblio
Prognostic implications of the detection of measurable residual disease and mutations based on next-generation sequencing in acute myeloid leukaemia with biallelic mutations of CEBPA. Br J Haematol. 2022.
Complete blood and urine paraprotein tests as response assessments in multiple myeloma patients treated with bortezomib, cyclophosphamide, and dexamethasone. Chronic Dis Transl Med. 2024;10(1):62-68.
. .